Related Experiment Videos
Treating severe sepsis with drotrecogin alfa (activated)
1St Thomas' Hospital, London SE1 7EH.
Hospital Medicine (London, England : 1998)
|April 3, 2003
Summary
Severe sepsis, a critical illness, has high mortality despite medical advances. Xigris (drotrecogin alfa (activated)) demonstrated a 6.1% absolute risk reduction in death, gaining EU marketing approval.
Area of Science:
- Critical Care Medicine
- Pharmacology
Background:
- Severe sepsis presents a significant clinical challenge with high mortality rates (30-50%).
- Despite advancements in critical care, effective treatments remain limited.
Purpose of the Study:
- To evaluate the efficacy of Xigris (drotrecogin alfa (activated)) in treating severe sepsis.
- To report on the clinical outcomes associated with drotrecogin alfa (activated) therapy.
Main Methods:
- Clinical trial data analysis.
- Assessment of mortality rates in severe sepsis patients.
Main Results:
- Drotrecogin alfa (activated) was associated with an absolute reduction in the risk of death of 6.1%.
- This finding supported its European Union marketing authorization in August 2002.
Conclusions:
- Drotrecogin alfa (activated) offers a potential therapeutic option for severe sepsis.
- The drug's approval signifies a step forward in managing this complex condition.